Drugs / synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00304096 | Dec 2005 → Jun 2007 | breast cancer | University of Virginia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00304096 ↗ |
| Modality | Vaccine | “peptide vaccine” NCT00304096 ↗ |
| Route | Subcutaneous | “subcutaneously and intradermally” NCT00304096 ↗ |